XML 34 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Data (Tables)
 9 Months Ended
Jun. 27, 2014
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information by Business Segment
Selected information by business segment was as follows:

Three Months Ended
 
Nine Months Ended

June 27,
2014

June 28,
2013
 
June 27,
2014
 
June 28,
2013
Net sales:



 
 
 
 
Specialty Pharmaceuticals
$
414.3


$
308.6

 
$
1,048.1

 
$
913.2

Global Medical Imaging
227.1


247.9

 
668.1

 
706.7

Net sales of operating segments (1)
641.4


556.5

 
1,716.2

 
1,619.9

Other (2)
11.7


13.5

 
34.9

 
39.4

Net sales
$
653.1


$
570.0

 
$
1,751.1

 
$
1,659.3

Operating income:



 
 
 
 
Specialty Pharmaceuticals
$
125.6


$
94.8

 
$
344.5

 
$
234.8

Global Medical Imaging
11.2


13.5

 
25.9

 
81.5

Segment operating income
136.8


108.3

 
370.4

 
316.3

Unallocated amounts:





 
 
 
 
Corporate and allocated expenses (3)          
(63.6
)

(43.7
)
 
(161.5
)
 
(109.4
)
Intangible asset amortization
(51.6
)

(8.9
)
 
(75.9
)
 
(26.6
)
Restructuring and related charges, net (4)
(24.2
)

(12.1
)
 
(54.0
)
 
(20.0
)
Separation costs
(1.8
)

(44.2
)
 
(6.6
)
 
(70.6
)
Operating loss
$
(4.4
)
 
$
(0.6
)
 
$
72.4

 
$
89.7

(1)
Amounts represent sales to external customers.
(2)
Represents products that were sold to Covidien, our former parent company, which is discussed in Note 14.
(3)
Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
(4)
Includes restructuring-related accelerated depreciation of $0.4 million and $0.8 million for the three months ended June 27, 2014 and June 28, 2013, respectively, and $0.5 million and $2.1 million for the nine months ended June 27, 2014 and June 28, 2013, respectively.